Abstract: Curare-type salts of the formula ##STR1## WHEREIN Ac is an alkyl carbonyl group containing 1 to 4 carbon atoms in the alkyl moiety and one ofR.sub.1 and R.sub.2, is a methylene group and the other is a group of the formula >N-R.sub.2 wherein R.sub.2 is an alkyl group containing 1 to 3 carbon atoms,A is halogen andR.sub.3 is an alkyl group containing 1 to 4 carbon atoms, or an alkyl group; andA process for the preparation thereof are disclosed.

Abstract: The invention relates to new .alpha.

Abstract: Racemic and optically active 1-alkyl-1,2,3,4,6,7,12,12b-octahydro-indolo[2,3-a]quinolizines of vasodilatory and haemodynamic effect are disclosed.

Abstract: The invention is directed to a new substituted derivative of .alpha.-ethylnyl-benzophenone, namely, the 3-iodo-.alpha.-ethynyl-benzhydrol which has high antifungal activity.

Abstract: The new compound 3,4,5-trimethoxy-.alpha.-ethynyl benzhydrol which has been found to be an effective fungicide.

Abstract: New triamino-androstanes with curare-type properties and a process for the preparation thereof are disclosed.

Abstract: .alpha.-ethynyl-benzhydrols, namely 2,5-dimethyl-.alpha.-ethynyl and 4-n-butyl-.alpha.-ethynyl benzhydrol, are made by reacting the starting benzophenone with acetylene in a solvent delivering no protons, in the presence of an alkali metal tertiary alcoholate, preferably potassium-ter.-butylate or potassium-tert.-amylate.

Abstract: A heart and vasotropic pharmaceutical of the formula: ##STR1## wherein R represents a hydrogen atom or an acyl group, preferably a C.sub.1-15 alkylcarbonyl, C.sub.2-6 alkenylcarbonyl, or a phenyl- (C.sub.1-5)-alkylcarbonyl group or a benzoyl group optionally substituted with halogen, trihalomethyl, C.sub.1-4 or nitroAnd pharmaceutically acceptable acid addition and quaternary salts thereof.

Abstract: New compounds of the general formula (I), ##STR1## wherein R.sub.1 and R.sub.2 each stand for a saturated or unsaturated, straight-chained or branched alkyl group, an aralkyl group, a saturated or unsaturated cycloalkyl group or an aryl group, orR.sub.1 and R.sub.2 together with the adjacent nitrogen atom may form an optionally substituted heterocyclic group optionally containing a further oxygen or nitrogen hetero atom,But if R.sub.1 stands for methyl, R.sub.2 may only stand for a group other than methyl, are prepared by reacting a compound of the general formula ##STR2## wherein X stands for halogen, with a secondary amine of the general formula (III),r.sub.1 --nh--r.sub.2 (iii)wherein R.sub.1 and R.sub.2 each have the same meanings as defined above.The new compounds of the general formula (I), as well as their pharmaceutical acceptable acid addition salts or quaternary ammonium salts are active primarily in the induction of liver microsomal enzyme, but they also possess antipyretic activity.

Abstract: A compound of the following formula: ##STR1## wherein X.sub.1 is hydrogen or mercapto;X.sub.2 is mercapto or acetylthio;X.sub.3 is hydrogen or acetylthio; andX.sub.4 is hydrogen, acetylthio or X.sub.3 and X.sub.4 together form a valence bond, but if X.sub.3 and X.sub.4 form a valence bond X.sub.2 is mercapto. The compounds are useful in the treatment of heavy-metal poisoning.

Abstract: New compounds of the general formula (I) ##STR1## wherein R stands for an alkyl group, have been prepared by reducing a compound of the general formula (II) ##STR2## wherein R stands for alkyl, B stands for H.sub.2 O or an X.sup.- anion derived from an acid, and if B is an X.sup.- anion, A represents hydrogen, whereas if B is H.sub.2 O, A represents an electron pair. If desired, the racemic compounds of the general formula (I) can be resolved to yield the corresponding optically active isomers. The free bases of the general formula (I) can be converted into their pharmaceutically acceptable salts, or the salts can be treated with an alkaline agent to yield the free bases.The compounds of the general formula (I) can be used in the therapy primarily as vasodilatating agents.

Abstract: New compounds of the general formula (I) ##STR1## wherein R.sub.1 stands for alkyl and R.sub.2 stands for carboxy, a functional carboxy derivative or a group convertible into carboxy group or a functional derivative thereof, have been prepared by reducing a compound of the general formula ##STR2## wherein R.sub.1 and R.sub.2 each have the same meanings as defined above and X.sup.- represents an anion derived from an acid, and optionally subjecting the obtained compound to hydrolysis. If desired, the racemic compounds of the general formula (I) can be resolved to yield the corresponding optically active isomers. The free bases of the general formula (I) can be converted into their pharmaceutically acceptable salts, or the salts can be treated with an alkaline agent to yield the free bases.The compounds of the general formula (I) can be used in the therapy primarily as vasodilatating agents.

Abstract: The invention relates to new eburnamenine derivatives of the general formula (I), ##STR1## wherein R.sub.1 stands for an alkyl group,R.sub.2 stands for a carboxy group, a functional carboxy derivative (preferably an ester group) or a group convertable into carboxy group or a functional derivative thereof (preferably cyano group), andX.sup.- is an anion derived from an acid,And the corresponding free bases.These compounds are valuable intermediates of the preparation of eburnamenine derivatives with advantageous therapeutical effects.The above compounds are prepared as follows: a compound of the general formula (II), ##STR2## wherein R.sub.1 has the same meanings as defined above, is reacted with a compound of the general formula (III), ##STR3## wherein R.sub.2 has the same meanings as defined above and Y is halogen, and, if desired, a thus-obtained compound of the general formula (I), wherein R.sub.1 and R.sub.2 each have the same meanings as defined above and X.sup.

Abstract: The invention relates to new indolo-quinolizidine derivatives of the general formula (I) or salts or optically active isomers thereof, ##STR1## wherein R stands for an alkyl group, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AS WELL AS TO A PROCESS FOR THE PREPARATION THEREOF.The new compounds according to the invention possess vasodilatating and hypotensive effects and can be used in the therapy as medicines. The new compounds according to the invention are completely devoid of harmful side-effects.

Abstract: The invention relates to new xanthene-9-carboxylates of the formula (I), ##STR1## wherein R.sub.1 and R.sub.3 are the same or different and each can represent a lower alkyl group,R.sub.2 is a lower alkyl group or a group of the formula (VI), ##STR2## WHEREIN M IS AN INTEGER OF 2 TO 5, OR R.sub.1 and R.sub.2 form, together with the adjacent nitrogen atom, a five- or six-membered heterocyclic group, and n and m each represent integers of 2 to 5, or salts thereof. These compounds possess cholinolytic and bronchospasmolytic effects and are completely devoid of harmful side-effects. Thus these compounds can be used to great advantage in therapy. The new compounds of the formula (I) or their salts can be prepared by reacting a diaminoalcohol of the formula (III), ##STR3## wherein R.sub.2 is lower alkyl or a group of formula -(CH.sub.2).sub.m -OH, with a reactive derivative of xanthene-9-carboxylic acid, and, if desired, converting the obtained product into its salt.

Abstract: An N-substituted carbonyl tetrahydrobenzodiazepines having ethoxycarbonyl, formyl, carbamoyl or methyl carbamoyl as the N.sup.4 substituent.

Abstract: New compounds of the formula ##STR1## are provided wherein R.sub.1 is hydrogen, and R.sub.2 stands for an alkyl group and optically active enanthiomers and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to xanthene-9-carboxylates of the formula ##STR1## wherein R.sub.1 and R.sub.3 may be the same or different and represent a lower alkyl group,n and m each are integers of 2 to 5, or pharmaceutically-effective salts thereof. The compounds according to the invention possess cholinolytic and bronchospasmolytic effects and are completely devoid of harmful side-effects. Thus these compounds can be used to great advantage in therapy.

Abstract: A compound of the formula: ##STR1## wherein Z is ethyl or vinyl,R.sub.1 and R.sub.2 are hydrogen, lower alkyl, lower alkenyl or trihalomethyl,R.sub.3 and R.sub.4 are hydrogen, lower alkyl, lower alkenyl, trihalomethyl, cyclopentyl, benzyl or phenyl, andR.sub.5 is lower alkyl, lower alkenyl, trihalomethyl, cyclopentyl, benzyl, or phenyl with the proviso that where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 each is hydrogen, R.sub.5 is not methyl attached to the 4-position of the benzene ring, or a pharmaceutically acceptable acid addition or quaternary ammonium salt thereof is disclosed as effective in the regulation of the liver microsomal enzyme system.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 stands for hydrogen or an acyl group, andR.sub.2 stands for an alkyl group are disclosed.A process for making the above compounds is also disclosed. The compounds are useful as vasodilatating agents for example.